| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10067-017-3596-7 |
| P698 | PubMed publication ID | 28342151 |
| P2093 | author name string | Yi Wang | |
| Jing Yang | |||
| Hao Li | |||
| Xin Lu | |||
| Chun Li | |||
| X Y Yang | |||
| C H Wang | |||
| Ming Gao | |||
| Rong Mu | |||
| Ping Wei | |||
| Dan Ke | |||
| Y F Wang | |||
| Ping Zhu | |||
| Rong Yang | |||
| Bin Jia | |||
| Lin Sun | |||
| H Y Chen | |||
| X M Liu | |||
| Rong Shu | |||
| X Y Wang | |||
| X Y Zhang | |||
| X F Li | |||
| Cong Ye | |||
| G C Wang | |||
| S X Hu | |||
| Yin Su | |||
| X R Wang | |||
| J F Li | |||
| J Y Lin | |||
| X Y Liu | |||
| C B Huang | |||
| H J Ji | |||
| B L Liu | |||
| Z G Li | |||
| Z L Zhang | |||
| L N Chen | |||
| J X Wang | |||
| Z B Li | |||
| L Z Wang | |||
| L F Cui | |||
| L J Song | |||
| F X Zhang | |||
| J T Liu | |||
| H T Jin | |||
| Bei Lai | |||
| Y D Tang | |||
| S L Han | |||
| G T Li | |||
| M Q Wei | |||
| J M Tao | |||
| P2860 | cites work | Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion | Q28217906 |
| EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis | Q33505914 | ||
| Mortality in rheumatoid arthritis: 2008 update. | Q34014809 | ||
| Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis | Q34648366 | ||
| The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. | Q35135831 | ||
| Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study | Q35605663 | ||
| Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study. | Q36193944 | ||
| Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus | Q36277899 | ||
| Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs | Q36361147 | ||
| Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis | Q36464352 | ||
| Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment | Q37131883 | ||
| Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs | Q37142052 | ||
| Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions | Q37415092 | ||
| Towards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment | Q37533298 | ||
| Progression of coronary artery atherosclerosis in rheumatoid arthritis: comparison with participants from the Multi-Ethnic Study of Atherosclerosis | Q37690404 | ||
| Classical cardiovascular disease risk factors associate with vascular function and morphology in rheumatoid arthritis: a six-year prospective study. | Q37691111 | ||
| An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy | Q39110166 | ||
| Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. | Q41109148 | ||
| Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients | Q41933145 | ||
| Chloroquine reduces blood pressure and forearm vascular resistance and increases forearm blood flow in healthy young adults | Q41938193 | ||
| Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? | Q41943988 | ||
| Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? | Q43255462 | ||
| Risk assessment for coronary heart disease in rheumatoid arthritis and osteoarthritis | Q45129671 | ||
| Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? | Q45235877 | ||
| Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. | Q45286659 | ||
| Insulin resistance and impaired beta cell function in rheumatoid arthritis | Q46161578 | ||
| Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation | Q46433523 | ||
| Biochemical characterization of ADP-ribose polymer metabolism in SLE. | Q51031046 | ||
| Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. | Q51126183 | ||
| Could cardiovascular disease risk stratification and management in rheumatoid arthritis be enhanced? | Q51174739 | ||
| TNFA −308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis | Q57307074 | ||
| What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated Peptide antibodies? | Q60622656 | ||
| Rheumatoid factor, smoking, and disease severity: associations with mortality in rheumatoid arthritis | Q60728508 | ||
| The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure | Q73912535 | ||
| Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years | Q78794833 | ||
| Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study | Q79850163 | ||
| Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy | Q82734935 | ||
| No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment | Q83430670 | ||
| Tumor necrosis factor α inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis | Q85720945 | ||
| Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis | Q85857547 | ||
| Atherosclerosis--an inflammatory disease | Q95816664 | ||
| P433 | issue | 5 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| cardiovascular disease | Q389735 | ||
| P304 | page(s) | 1023-1029 | |
| P577 | publication date | 2017-03-24 | |
| P1433 | published in | Clinical Rheumatology | Q15754927 |
| P1476 | title | Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China | |
| P478 | volume | 36 |
| Q88956497 | Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature |
| Q45796102 | Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis |
| Q55208303 | Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. |
| Q64092285 | Concordance between the Different Cardiovascular Risk Scores in People with Rheumatoid Arthritis and Psoriasis Arthritis |
Search more.